# Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

> **NCT06365970** · PHASE2 · WITHDRAWN · sponsor: **Ibrahim Halil Sahin**

## Conditions studied

- MMR-D/MSI-H Colorectal Cancers

## Interventions

- **DRUG:** Niraparib
- **DRUG:** Dostarlimab

## Key facts

- **NCT ID:** NCT06365970
- **Lead sponsor:** Ibrahim Halil Sahin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-01-31
- **Primary completion:** 2027-01
- **Final completion:** 2028-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Per drug sponsor request.
- **Last updated:** 2025-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06365970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06365970, "Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06365970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*